A team of scientists has uncovered the remarkable potential of a human antibody, mAb 3A6, in fighting Ebola virus infections.

Here, we discuss strategies to select the best therapeutic antigen targets, to optimize the structure of IgG antibodies and to design related or new structures with additional functions.

Caption Structure of the variable domains of the Cv2.1169 antibody (purple) in complex with the S protein domain involved in SARS-CoV-2 receptor binding (receptor binding domain or RBD in yellow ...

Antibodies usually have a Y-shaped structure, and these hypervariable regions are located in the tips of the Y, where they ...

“We computationally predict what mutations allow better binding to host receptors and better evasion of antibodies,” said Boston College Assistant Professor ... “We simulated the electronic structure ...

Recent research from the Florida State University Department of Chemistry and Biochemistry shows that a particular type of ...

The variable domain gene usage was diverse in these monoclonal antibodies. SAN DIEGO — An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha ...